Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRK6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,979.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector vials. The delivery order, issued on January 6, 2026, carries an ultimate completion date of January 28, 2026, with no set-aside designation. This award represents a single delivery order issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy established to provide pharmaceutical supplies to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group, registered in the System for Award Management since 2001, serves as a critical supplier within the federal pharmaceutical supply chain and holds a single-award IDC under the PPV-G GEN V program valued at $499,999,999 through December 31, 2036. The company's comprehensive product portfolio includes branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with demonstrated capability to fulfill diverse medical supply requirements across military healthcare operations. This delivery order for Xolair, a biologic immunosuppressant used in the treatment of allergic conditions, exemplifies the routine fulfillment of specialized pharmaceutical needs through the Defense Logistics Agency's prime vendor contracting vehicle.
Quick answers
Who was awarded contract SPE2DR26FRRK6?
SPE2DR26FRRK6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FRRK6 worth?
The government has obligated $13,980 on SPE2DR26FRRK6.
Is contract SPE2DR26FRRK6 an order under another contract?
Yes. SPE2DR26FRRK6 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRK6 competed?
The extent of competition for SPE2DR26FRRK6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award